BeyondSpring Reports $6.7 Million Net Loss in Q1 2026, No Revenue from Continuing Operations

BeyondSpring Inc. reported a consolidated net loss of $6.7 million for the three months ended March 31, 2026, a significant decline from a net income of $1.2 million during the same period in 2025. The previous year's results included a $7.0 million gain from the sale of subsidiary interests, which was not replicated in the latest quarter. The company did not generate any revenue from its continuing operations during the first quarter of 2026, consistent with the previous year, while its discontinued operations, primarily from SEED Therapeutics, generated $0.5 million in revenue.

Operating expenses for the first quarter of 2026 totaled $2.3 million, a decrease of 14% compared to $2.6 million in the prior year. Research and development expenses rose by 23% to $1.1 million, driven by increased drug manufacturing activities, while general and administrative expenses decreased by 33% to $1.2 million, attributed to lower incentive compensation and professional service costs. The company’s loss from discontinued operations increased to $4.3 million, up from $3.2 million in the prior year, reflecting ongoing challenges in the SEED segment.

In terms of financial position, BeyondSpring's total assets decreased to $18.4 million as of March 31, 2026, down from $25.9 million at the end of 2025. The company’s cash and cash equivalents fell to $4.0 million, alongside short-term investments of $3.8 million. The accumulated deficit increased to $410.6 million, reflecting the ongoing investment in research and development without corresponding revenue generation. The company’s total liabilities also decreased slightly to $48.8 million.

Strategically, BeyondSpring is focused on advancing its lead asset, Plinabulin, which is in clinical trials for various cancer indications. The company is preparing for a confirmatory global Phase 3 study (DUBLIN-4) following the successful completion of the DUBLIN-3 study, which demonstrated significant survival benefits for patients with non-small cell lung cancer. BeyondSpring is also exploring strategic partnerships and financing options to support its operations and product development, as it anticipates continued operating losses in the near future.

Looking ahead, BeyondSpring expects to incur significant expenses as it continues to develop its product candidates and seek regulatory approvals. The company is actively evaluating various financing alternatives to support its operations, including potential equity and debt financing, licensing arrangements, and strategic partnerships. However, it acknowledges the uncertainty surrounding market conditions and the potential impact on its ability to secure necessary funding.